AbbVie Adds Alzheimer’s Opportunity With $1.4bn Aliada Buy
Pharma Sees Best-In-Class Potential
Aliada’s ALIA-1758 addresses the same target as Lilly’s Kisunla, but is paired with a blood-brain barrier transport technology that may offer high affinity and potential for lower dosing.
